Drugs / CERE-110
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00087789 | Jun 2004 → May 2010 | Alzheimer disease | Sangamo Therapeutics | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00876863 | Nov 2008 → Aug 2015 | Alzheimer disease | Sangamo Therapeutics | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CERE-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00087789 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-Associated Virus Delivery” NCT00087789 ↗ |
| Route | Other | “intracerebral injections” PMID 29582053 ↗ Jul 2018 |
| Target | NGF | “CERE-110 uses a virus to transfer a gene that makes Nerve Growth Factor (NGF), a protein that may make nerve cells in the brain healthier and protect them from dying.” NCT00876863 ↗ |